OncoImmunology
Volume 9, 2020 - Issue 1
Editorial
FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatin
Jonathan G. Pola Gustave Roussy Comprehensive Cancer Institute, Villejuif, France;b Institut National De La Santé Et De La Recherche Médicale (INSERM), Paris, France;c Centre De Recherche Des Cordeliers, Paris, France;d Equipe “Metabolism, Cancer & Immunity” Labellisée Par La Ligue Nationale Contre Le Cancer, Paris, France;e Université De Paris, Paris, France;f Sorbonne Université, Paris, France;g Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France
https://orcid.org/0000-0002-8355-7562
https://orcid.org/0000-0002-8355-7562, & Guido Kroemera Gustave Roussy Comprehensive Cancer Institute, Villejuif, France;b Institut National De La Santé Et De La Recherche Médicale (INSERM), Paris, France;c Centre De Recherche Des Cordeliers, Paris, France;d Equipe “Metabolism, Cancer & Immunity” Labellisée Par La Ligue Nationale Contre Le Cancer, Paris, France;e Université De Paris, Paris, France;f Sorbonne Université, Paris, France;g Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France;i Pôle De Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France;j Suzhou Institute for Systems Medicine, Chinese Academy of Sciences, Suzhou, China;k Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, SwedenCorrespondence[email protected]
https://orcid.org/0000-0002-9334-4405
https://orcid.org/0000-0002-9334-4405